Clinical trials: Moderate-to-severe Psoriasis
Plaque Psoriasis
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
An open label, single arm study to evaluate the study and efficacy of efalizumab in combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in combination with NB-UVB three times per week.
- Trial name
- NCT00302445
- Testing
- Efalizumab, Narrow Band Phototherapy
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Psoriasis
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00338754
- Testing
- Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks
- Where
- 8 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Abbott
Psoriasis
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
- Trial name
- NCT03535194
- Testing
- Mirikizumab, Secukinumab
- Where
- 178 sites in United States, Argentina and 14 more
- Volunteers
- 1,484 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis.
- Trial name
- IASOS (NCT05190419)
- Testing
- Orismilast modified release tablets
- Where
- 34 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- UNION therapeutics
Psoriasis
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis.
- Trial name
- NCT02763969
- Testing
- BMS-986202, Interferon alpha-2a recombinant, Famotidine
- Where
- 2 sites in Australia
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 1 (NCT01194219)
- Testing
- Apremilast, Topical treatments or phototherapy
- Volunteers
- 844 people
- Sponsor
- Amgen
Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis
- Trial name
- CADMUS Jr (NCT02698475)
- Testing
- Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Stable Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to…
- Trial name
- NCT02949388
- Testing
- 400 mg (200 mg BID), 300 mg (150 mg BID)
- Where
- 34 sites in United States
- Volunteers
- 199 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed.
- Trial name
- NCT03431974
- Testing
- LD-Aminopterin oral capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Syntrix Biosystems, Inc.
Chronic Scalp Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- SCALP (NCT02267135)
- Testing
- Secukinumab 300 mg
- Where
- 17 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment…
- Trial name
- MECAP (NCT07129382)
- Testing
- CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）
- Where
- 11 sites in China
- Volunteers
- 220 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Psoriasis
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.
- Trial name
- DCE (NCT05065762)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis.
- Trial name
- Illuminate (NCT05896527)
- Testing
- DC-806
- Where
- 56 sites in United States, Canada and 6 more
- Volunteers
- 229 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy
The efficacy of TNF alfa inhibitors in the treatment of psoriasis has been documented in many studies. Their effect on dendritic cells has been scarcely studied.
- Trial name
- ELIDACE (NCT01237262)
- Testing
- Adalimumab, etanercept, infliximab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Padova
Psoriasis
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT05645627
- Testing
- IBI112
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Psoriasis, Plaque Type Psoriasis
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
- Conditions
- Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
- Trial name
- AURIEL-PsO (NCT02660580)
- Testing
- MSB11022, Humira®
- Where
- 76 sites in United States, Bulgaria and 10 more
- Volunteers
- 443 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.